3 Drugs Stocks On The Rise
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Two out of the three major indices are trading lower today with the
Dow Jones Industrial Average
(
^DJI
) trading down 131 points (-0.7%) at 17,945 as of Thursday, March 19, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 912 issues advancing vs. 2,103 declining with 122 unchanged.
The Drugs industry currently sits up 1.6% versus the S&P 500, which is down 0.6%. Top gainers within the industry include
(
), up 30.9%,
(
), up 6.0%,
(
), up 4.0%,
(
), up 3.0% and
(
), up 2.0%. On the negative front, top decliners within the industry include
(
), down 2.4%,
(
), down 1.7%,
(
), down 1.2%,
Teva Pharmaceutical Industries
(
), down 1.1% and
(
), down 0.5%.
TheStreet would like to highlight 3 stocks pushing the industry higher today:
3.
(
) is one of the companies pushing the Drugs industry higher today. As of noon trading, Amgen is up $1.50 (0.9%) to $168.04 on average volume. Thus far, 1.4 million shares of Amgen exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $166.97-$168.89 after having opened the day at $167.67 as compared to the previous trading day's close of $166.54.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. Amgen has a market cap of $123.7 billion and is part of the health care sector. Shares are up 4.5% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold.
TheStreet Ratings rates
Amgen
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
(
) is up $2.14 (1.7%) to $124.82 on average volume. Thus far, 2.8 million shares of Celgene exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $123.65-$125.10 after having opened the day at $123.80 as compared to the previous trading day's close of $122.68.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $96.9 billion and is part of the health care sector. Shares are up 9.7% year-to-date as of the close of trading on Wednesday. Currently there are 16 analysts who rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.
TheStreet Ratings rates
Celgene
as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
(
) is up $1.18 (2.0%) to $61.07 on average volume. Thus far, 5.6 million shares of AbbVie exchanged hands as compared to its average daily volume of 11.5 million shares. The stock has ranged in price between $59.99-$61.22 after having opened the day at $60.06 as compared to the previous trading day's close of $59.89.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $95.2 billion and is part of the health care sector. Shares are down 8.5% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts who rate AbbVie a buy, no analysts rate it a sell, and 3 rate it a hold.
TheStreet Ratings rates
AbbVie
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and generally higher debt management risk. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
null